GLP-1 & MetabolicMW: 4731.4 g/mol
Retatrutide (Triple GIP / GLP-1 / Glucagon Agonist)
A next-generation triple agonist targeting GIP, GLP-1, and Glucagon receptors simultaneously, representing the frontier of metabolic research.
Biological Mechanism
Stimulates energy expenditure and hepatic lipid oxidation via glucagon activation, while maintaining appetite suppression through GIP/GLP-1.
Common Research Dosing
1.0 mg – 4.0 mg
Reconstitute with ~2 mL BAC water
Storage & Reconstitution
Lyophilized at -20°C. Protect from temperature fluctuations.
Audited Vendor Rankings
Top Verified Vendors for Retatrutide
Scientific Context: Retatrutide (Triple GIP / GLP-1 / Glucagon Agonist) is referenced strictly for laboratory research, cell culture studies, and in-vitro analytical testing. It is not licensed for human medical or therapeutic use.